Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 14/20 | 0.45 |
| ▸ | NOS2 | P35228 | 8/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8098264 | 0.85 | NOS3 (0.59) | NOS3NOS2 | |
| SCHEMBL14010700 | 0.82 | NOS3 (0.41) | NOS3NOS2KDM1A | |
| SCHEMBL8233735 | 0.80 | NOS2 (0.71) | NOS3NOS2KDM1A | |
| Hydrochloric Acid SCHEMBL8106479 | 0.80 | NOS2 (0.63) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8105956 | 0.77 | NOS3 (0.40) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8090005 | 0.75 | NOS2 (0.64) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8098981 | 0.75 | NOS2 (0.64) | NOS3NOS2 | |
| SCHEMBL5005082 | 0.73 | NOS3 (0.71) | NOS3NOS2KDM1A | |
| Hydrochloric Acid SCHEMBL8090909 | 0.73 | NOS2 (0.36) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8090630 | 0.73 | NOS2 (0.37) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957462-A2 | NOVEL 2-AMINO-HETEROCYCLES UDEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | Astra Zeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | NOS3 2189/4885NOS2 1471/4885KDM1A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.